Applications of Isonicotinoyl Chloride Hydrochloride in Industrial Manufacturing

Isonicotinoyl Chloride Hydrochloride plays a pivotal role in the advanced synthesis of specialty chemicals, pharmaceuticals, and fine organic intermediates. Its unique reactivity and controlled purity allow for integration into tightly regulated production environments, supporting end users across key industrial sectors. Below we outline several established downstream application scenarios reflecting industry-specific compliance, accurate dosing recommendations, processing details, and manufactured product types.

1. Pharmaceutical Synthesis: Anti-Tubercular Drug Intermediates

Used as a critical starting material in the preparation of active pharmaceutical ingredients (APIs) such as isoniazid, this compound serves as an acylating agent in API synthesis. Manufacturers deploy it during key transformation steps that build the target pharmacophore, and its purity directly impacts batch consistency. Due to regulatory scrutiny in pharmaceutical intermediate production, both material and process quality must meet strict international standards to ensure suitability for large-scale, GMP-compliant drug manufacturing.

Industry compliance standards

• ICH Q7 Good Manufacturing Practices for Active Pharmaceutical Ingredients
• European Pharmacopoeia & USP standards for intermediates
• FDA cGMP 21 CFR Part 210/211
• EDQM/WHO Technical Guidelines for API intermediates

Typical usage ratio

• 0.85 to 1.05 molar equivalents per isonicotinic acid unit; the precise ratio depends on targeted yields, reaction kinetics, and impurity profile control

Downstream process integration

• Charged after preliminary solvent conditioning in acylation reaction vessels during the key intermediate step for forming the isoniazid precursor
• Introduced under inert atmosphere at controlled temperature to moderate reaction exotherm and optimize conversion rate

Final product types

• Pharmaceutical intermediates for isoniazid production
• Finished anti-tubercular APIs
• Solid oral dosage forms (tablets, capsules) for tuberculosis treatment

2. Agrochemical Intermediate Manufacturing

The compound is leveraged in multi-step agrochemical synthesis as a custom building block for the preparation of pyridine-type herbicide and insecticide intermediates. Its controlled reactivity permits selectivity in introducing isonicotinoyl groups, reducing downstream purification burdens in technical grade pesticide precursor lines. Agricultural chemical manufacturers must uphold strict quality benchmarks, especially where residual intermediates might migrate to the final crop-protection formulations.

Industry compliance standards

• FAO/WHO Specifications for Pesticide Technical Material
• ISO 9001:2015 Certified Quality Management
• REACH Regulation (EC) No 1907/2006 for intermediates
• National Agrochemical Residue Control requirements

Typical usage ratio

• 0.9–1.2 stoichiometric equivalents relative to nucleophilic coupling agents; modification based on desired conversion and impurity clearance strategy

Downstream process integration

• Dosed during the coupling and acylation stages when assembling the core structure of pyridyl-derived herbicide intermediates
• Reacted in closed reactors under controlled pH and temperature with solvent recovery protocols for repeat batch operation

Final product types

• Agrochemical intermediates (herbicide, insecticide precursors)
• Technical active ingredients for formulating crop protection products
• Bulk pre-formulation concentrates

3. API Intermediate for Anti-Infective Drugs (Second-Line Tuberculosis Agents)

Many manufacturers employ this compound for the acylation of amine or hydrazide groups in second-line tuberculosis drug candidates, where the intermediate’s structural influence supports customized pharmacokinetics and toxicity profiles. Its integration occurs under validated process parameters to satisfy multi-stage quality checkpoints from raw material receipt through intermediate formation and isolation, strictly conforming to pharmaceutical traceability rules.

Industry compliance standards

• EU GMP Part II for API intermediates
• China NMPA Drug Master File requirements
• US FDA Type IV Drug Master Files
• International Conference on Harmonisation (ICH) Q3A for Impurities in APIs

Typical usage ratio

• 1.00–1.10 molar equivalents per amine/hydrazide group, adjusted per lot assay and impurity tolerance for critical intermediate stages

Downstream process integration

• Added in later stages of multi-step synthesis at elevated temperature with controlled addition rates
• Material enters reaction post-deprotection of amine/hydrazide substrates to achieve site-specific acylation

Final product types

• Advanced intermediates for anti-infective APIs (e.g., ethionamide, prothionamide precursors)
• Final APIs for resistant-tuberculosis therapies
• Oral and injectable dosage forms for hospital and public health supply chains

4. Fine Chemical Synthesis of Pyridine-Based Ligands

The material supports the highly selective acylation steps required for synthesizing specialized pyridine ligands used by catalyst and organometallic compound producers. These ligands play a crucial role in the construction of homogeneous catalysts for pharma and specialty chemical applications. Downstream formulators closely monitor every batch for trace side products, making lot-to-lot consistency and documentation essential.

Industry compliance standards

• ISO 9001:2015 Quality Management System for Fine Chemicals
• Internal corporate QC protocols conforming to customer-specific ligand purity and trace metal limits
• Supplier qualification standards set by global catalyst manufacturers

Typical usage ratio

• 0.95–1.10 stoichiometric equivalents, fine-tuned based on ligand synthesis route and functional group tolerance criteria

Downstream process integration

• Material introduced during the controlled acylation sequence in anhydrous conditions
• Synthesized ligands undergo in situ purification via crystallization or preparative chromatography immediately post-acylation

Final product types

• Pyridine-based ligands for homogeneous catalysts
• Catalyst precursors for transition metal complex formation
• Specialty intermediates for medicinal and synthetic chemistry use